Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eikon Therapeutics, Inc.EIKN · Entity 5380 | Chief Operating Officer | March 02, 2026 | March 04, 2026 |
| Merck & Co., Inc.MRK · Entity 2807 | EVP - Chief Strategy Officer | May 04, 2024 | May 06, 2024 |
| REVVITY, INC.RVTY · Entity 3382 | Director | May 07, 2026 | May 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eikon Therapeutics, Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.88 · Expires 2036-03-01 | Direct | 87,157 |
Reported balance
After 2026-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 87,157 · Balance 87,157 F1: 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date.
Merck & Co., Inc.
Report date May 04, 2024 · Filed May 06, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,058.195 |
Reported balance
After 2024-05-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-05-04 · Exercise / conversion · Acquired 887 · Balance 24,058.195 |
| Common StockSEC Table I · non-derivative | Direct | 23,621.195 |
Reported balance
After 2024-05-04 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2024-05-04 · Tax withholding · Disposed 437 · Balance 23,621.195 F1: Holdings include shares acquired in dividend reinvestment transactions. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2024-05-04 | Direct | 0 |
Reported balance
After 2024-05-04 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-05-04 · Exercise / conversion · Disposed 887 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4: These restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. |
| Common StockSEC Table I · non-derivative | IndirectBy Child | 6.292 |
Reported balance
Holding disclosure · report date 2024-05-04 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 6.292 |
| Common StockSEC Table I · non-derivative | IndirectBy Child | 6.292 |
Reported balance
Holding disclosure · report date 2024-05-04 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 6.292 |
| Common Stock - 401(k) PlanSEC Table I · non-derivative | IndirectBy 401(k) | 866.5359 |
Reported balance
Holding disclosure · report date 2024-05-04 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 866.5359 F2: Includes shares acquired and dividends earned through April 5, 2024 in the Merck U.S. Savings Plan, a 401(k) plan. |
| Common Stock - 401(k) PlanSEC Table I · non-derivative | IndirectBy Spouse | 697.4925 |
Reported balance
Holding disclosure · report date 2024-05-04 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 697.4925 F2: Includes shares acquired and dividends earned through April 5, 2024 in the Merck U.S. Savings Plan, a 401(k) plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Holdings include shares acquired in dividend reinvestment transactions.
F2: Includes shares acquired and dividends earned through April 5, 2024 in the Merck U.S. Savings Plan, a 401(k) plan.
F3: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
F4: These restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024.
REVVITY, INC.
Report date May 07, 2026 · Filed May 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,368 |
Ending reported balance
After 2026-05-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-05-07 · Grant · Acquired 1,015 · Balance 6,103 F1: The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2027, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control. Row 2 · 2026-05-07 · Grant · Acquired 1,265 · Balance 7,368 |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2027, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 07, 2026 Filed May 11, 2026 20:05 UTC | REVVITY, INC. RVTY · Entity 3382 | GrantCommon Stock | 1,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-216733 · ownership.xml · nonDerivative · entry 2 Klobuchar Michael A · CIK 0001871957 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,368 Read SEC document |
| May 07, 2026 Filed May 11, 2026 20:05 UTC | REVVITY, INC. RVTY · Entity 3382 | GrantCommon Stock | 1,015 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-216733 · ownership.xml · nonDerivative · entry 1 Klobuchar Michael A · CIK 0001871957 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,103 F1 · shares: The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 27, 2027, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 22:04 UTC | Eikon Therapeutics, Inc. EIKN · Entity 5380 | GrantStock Option (Right to Buy) · Derivative | 87,157 | $0.00 Strike: $14.88 | $0.00 |
DisclosureSEC source: 0001193125-26-091798 · ownership.xml · derivative · entry 1 Klobuchar Michael A · CIK 0001871957 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,157 Underlying: Common Stock · 87,157 shares Expires 2036-03-01 F1 · derivative.exercise_date: 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date. Read SEC document |
| April 30, 2025 Filed May 1, 2025 20:05 UTC | REVVITY, INC. RVTY · Entity 3382 | GrantCommon Stock | 1,338 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-061818 · ownership.xml · nonDerivative · entry 2 Klobuchar Michael A · CIK 0001871957 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,088 Read SEC document |
| April 30, 2025 Filed May 1, 2025 20:05 UTC | REVVITY, INC. RVTY · Entity 3382 | GrantCommon Stock | 1,074 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-061818 · ownership.xml · nonDerivative · entry 1 Klobuchar Michael A · CIK 0001871957 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,750 F1 · shares: The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 28, 2026, the scheduled date for the issuer's next annual meeting of shareholders, subject to the Reporting Person's continued service through such date or, if earlier, upon the Reporting Person's death, disability or qualifying retirement, or the termination of the Reporting Person's service within 12 months following a change in control. Read SEC document |
| May 04, 2024 Filed May 6, 2024 20:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 887 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-014265 · form4.xml · derivative · entry 7 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 887 shares Expires 2024-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. Read SEC document |
| May 04, 2024 Filed May 6, 2024 20:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 437 | $127.51 | $55,721.87 |
DisclosureSEC source: 0001127602-24-014265 · form4.xml · nonDerivative · entry 2 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,621.195 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 04, 2024 Filed May 6, 2024 20:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 887 | $127.51 | $113,101.37 |
DisclosureSEC source: 0001127602-24-014265 · form4.xml · nonDerivative · entry 1 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,058.195 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2024 Filed May 2, 2024 20:05 UTC | REVVITY, INC. RVTY · Entity 3382 | GrantCommon Stock | 1,218 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-052073 · ownership.xml · nonDerivative · entry 2 Klobuchar Michael A · CIK 0001871957 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,676 Read SEC document |
| May 01, 2024 Filed May 2, 2024 20:05 UTC | REVVITY, INC. RVTY · Entity 3382 | GrantCommon Stock | 977 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-052073 · ownership.xml · nonDerivative · entry 1 Klobuchar Michael A · CIK 0001871957 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,458 F1 · shares: The Reporting Person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 22, 2025, the scheduled date for the issuer's next annual meeting of shareholders, subject to the reporting person's continued service through such date or, if earlier, upon the reporting person's death, disability or qualifying retirement, or the termination of the reporting person's service within 12 months following a change in control. Read SEC document |
| April 30, 2024 Filed May 2, 2024 20:09 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 20,508 | $0.00 Strike: $129.22 | $0.00 |
DisclosureSEC source: 0001127602-24-013930 · form4.xml · derivative · entry 6 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,508 Underlying: Common Stock · 20,508 shares Expires 2034-04-29 F3 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on 4/30/2025, 4/30/2026 and 4/30/2027. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:05 UTC | REVVITY, INC. RVTY · Entity 3382 | GrantCommon Stock | 264 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-016346 · ownership.xml · nonDerivative · entry 2 Klobuchar Michael A · CIK 0001871957 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 481 Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:05 UTC | REVVITY, INC. RVTY · Entity 3382 | GrantCommon Stock | 217 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-016346 · ownership.xml · nonDerivative · entry 1 Klobuchar Michael A · CIK 0001871957 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217 F1 · shares: The reporting person was granted restricted stock units, with each unit representing a contingent right to receive one share of the issuer's common stock. The grant of restricted stock units will fully vest on April 23, 2024, the scheduled date for the issuer's next annual meeting of shareholders, subject to the reporting person's continued service through such date or, if earlier, upon the reporting person's death, disability or qualifying retirement, or the termination of the reporting person's service within 12 months following a change in control. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 21:01 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 3,896 | $119.43 | $465,299.28 |
DisclosureSEC source: 0001127602-24-002008 · form4.xml · nonDerivative · entry 1 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,098.138 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/21. Performance shares were paid out at 161 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2023. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 04, 2023 Filed May 5, 2023 21:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 885 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014751 · form4.xml · derivative · entry 7 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 887 Underlying: Common Stock · 885 shares Expires 2024-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. Read SEC document |
| May 04, 2023 Filed May 5, 2023 21:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 436 | $118.22 | $51,543.92 |
DisclosureSEC source: 0001127602-23-014751 · form4.xml · nonDerivative · entry 4 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,039.999 Read SEC document |
| May 04, 2023 Filed May 5, 2023 21:06 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 885 | $118.22 | $104,624.70 |
DisclosureSEC source: 0001127602-23-014751 · form4.xml · nonDerivative · entry 3 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,475.999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2023 Filed May 4, 2023 22:26 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 20,747 | $0.00 Strike: $117.89 | $0.00 |
DisclosureSEC source: 0001127602-23-014571 · form4.xml · derivative · entry 6 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,747 Underlying: Common Stock · 20,747 shares Expires 2033-05-01 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/2/2024, 5/2/2025 and 5/2/2026. Read SEC document |
| May 01, 2023 Filed May 3, 2023 19:00 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 866 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-014204 · form4.xml · derivative · entry 7 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 866 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| May 01, 2023 Filed May 3, 2023 19:00 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 427 | $115.47 | $49,305.69 |
DisclosureSEC source: 0001127602-23-014204 · form4.xml · nonDerivative · entry 4 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,590.999 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 01, 2023 Filed May 3, 2023 19:00 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 866 | $115.47 | $99,997.02 |
DisclosureSEC source: 0001127602-23-014204 · form4.xml · nonDerivative · entry 3 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,901.461 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2023 Filed Jan 25, 2023 21:41 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 2,651 | $109.88 | $291,291.88 |
DisclosureSEC source: 0001127602-23-002197 · form4.xml · nonDerivative · entry 1 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,989.93 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/31/20. Performance shares were paid out at 110 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2022. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:07 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 885 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013522 · form4.xml · derivative · entry 7 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,772 Underlying: Common Stock · 885 shares Expires 2024-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/4/2022, 5/4/2023 and 5/4/2024. Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:07 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 436 | $87.10 | $37,975.60 |
DisclosureSEC source: 0001127602-22-013522 · form4.xml · nonDerivative · entry 2 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,338.93 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:07 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 885 | $87.10 | $77,083.50 |
DisclosureSEC source: 0001127602-22-013522 · form4.xml · nonDerivative · entry 1 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,774.93 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2022 Filed May 4, 2022 20:53 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 773 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013216 · form4.xml · derivative · entry 7 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 773 shares Expires 2022-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vested and were distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/3/2020, 5/3/2021 and 5/3/2022. Read SEC document |
| May 03, 2022 Filed May 4, 2022 20:53 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 381 | $87.65 | $33,394.65 |
DisclosureSEC source: 0001127602-22-013216 · form4.xml · nonDerivative · entry 2 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,889.93 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 03, 2022 Filed May 4, 2022 20:53 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 773 | $87.65 | $67,753.45 |
DisclosureSEC source: 0001127602-22-013216 · form4.xml · nonDerivative · entry 1 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,270.93 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:07 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 25,243 | $0.00 Strike: $87.10 | $0.00 |
DisclosureSEC source: 0001127602-22-013522 · form4.xml · derivative · entry 8 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,243 Underlying: Common Stock · 25,243 shares Expires 2032-05-02 F5 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/3/2023, 5/3/2024 and 5/3/2025. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:13 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionRestricted Stock Unit · Derivative | 866 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-013019 · form4.xml · derivative · entry 7 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 866 Underlying: Common Stock · 866 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/1/2021, 5/1/2022 and 5/1/2023. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:13 UTC | Merck & Co., Inc. MRK · Entity 2807 | Tax withholdingCommon Stock | 427 | $88.69 | $37,870.63 |
DisclosureSEC source: 0001127602-22-013019 · form4.xml · nonDerivative · entry 2 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,497.93 F1 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:13 UTC | Merck & Co., Inc. MRK · Entity 2807 | Exercise / conversionCommon Stock | 866 | $88.69 | $76,805.54 |
DisclosureSEC source: 0001127602-22-013019 · form4.xml · nonDerivative · entry 1 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,924.93 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 21:22 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantCommon Stock | 2,994 | $73.51 | $220,088.94 |
DisclosureSEC source: 0001127602-22-007016 · form4.xml · nonDerivative · entry 1 Klobuchar Michael A · CIK 0001871957 · EVP - Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,058.93 F1 · shares: Distribution of net after tax shares of common stock on satisfaction of performance criteria for performance share units granted on 3/29/19. Performance shares were paid out at 140 percent of target awards. Includes dividends accrued over the three-year performance period ending December 31, 2021. F2 · balance_after: Holdings include shares acquired in dividend reinvestment transactions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.